— Role of TP53 abnormalities in immunotherapy response in AML highlighted — Role of TP53 abnormalities in immunotherapy response in AML highlighted

See the original post here:
MacroGenics Announces Flotetuzumab Publication in Blood Advances

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh